As TGF-β exerts a wide range of cellular effects in various organ systems, the therapeutic modalities to dampen its effects in CKD would need to consider the balanced duality of its homeostatic and pathogenic functions of TGF-β. The gene discussed is TGFB1; the disease is chronic kidney disease.